CONTEXT: PTEN, a tumour suppressor gene located on chromosome 10q23, develops somatic mutations in various tumours and tumour cell lines including brain, endometrium, prostate, breast, kidney, thyroid, liver, and melanoma. OBJECTIVES: To investigate the mutational profile of this gene further, as well as its role in tumour progression in melanoma. DESIGN, SETTINGS: We examined 21 metastatic melanoma samples for 10q23 allelic losses and PTEN sequence alterations. Additionally, we screened these samples for mutations in CDKN2A, a gene in which alterations are well documented in primary melanoma as well as in the germline of familial melanoma. RESULTS: Loss of heterozygosity (LOH) at 10q23 was observed in 33% (7/21) of the samples tested. We identified four sequence alterations in PTEN (19%) and two in CDKN2A (9.5%). Of interest, only one case showed mutations in both genes. CONCLUSIONS: These data support the notion that PTEN alterations occur in some metastatic melanomas, and that mutation of this gene plays a role in the progression of some forms of melanoma.
CONTEXT: PTEN, a tumour suppressor gene located on chromosome 10q23, develops somatic mutations in various tumours and tumour cell lines including brain, endometrium, prostate, breast, kidney, thyroid, liver, and melanoma. OBJECTIVES: To investigate the mutational profile of this gene further, as well as its role in tumour progression in melanoma. DESIGN, SETTINGS: We examined 21 metastatic melanoma samples for 10q23 allelic losses and PTEN sequence alterations. Additionally, we screened these samples for mutations in CDKN2A, a gene in which alterations are well documented in primary melanoma as well as in the germline of familial melanoma. RESULTS: Loss of heterozygosity (LOH) at 10q23 was observed in 33% (7/21) of the samples tested. We identified four sequence alterations in PTEN (19%) and two in CDKN2A (9.5%). Of interest, only one case showed mutations in both genes. CONCLUSIONS: These data support the notion that PTEN alterations occur in some metastatic melanomas, and that mutation of this gene plays a role in the progression of some forms of melanoma.
Authors: H C Tsou; X L Ping; X X Xie; A C Gruener; H Zhang; R Nini; K Swisshelm; V Sybert; T M Diamond; R Sutphen; M Peacocke Journal: Hum Genet Date: 1998-04 Impact factor: 4.132
Authors: J Monzon; L Liu; H Brill; A M Goldstein; M A Tucker; L From; J McLaughlin; D Hogg; N J Lassam Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S Bova Journal: Cancer Res Date: 1998-01-15 Impact factor: 12.701
Authors: E D Lynch; E A Ostermeyer; M K Lee; J F Arena; H Ji; J Dann; K Swisshelm; D Suchard; P M MacLeod; S Kvinnsland; B T Gjertsen; K Heimdal; H Lubs; P Møller; M C King Journal: Am J Hum Genet Date: 1997-12 Impact factor: 11.025
Authors: D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck Journal: Cancer Res Date: 1997-12-01 Impact factor: 12.701
Authors: M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks Journal: Proc Natl Acad Sci U S A Date: 1998-11-10 Impact factor: 11.205
Authors: Jee Hee Son; Bo Young Chung; Min Je Jung; Yong Won Choi; Hye One Kim; Chun Wook Park Journal: Ann Dermatol Date: 2019-05-01 Impact factor: 1.444
Authors: Yun Wang; John J Digiovanna; Jere B Stern; Thomas J Hornyak; Mark Raffeld; Sikandar G Khan; Kyu-Seon Oh; M Christine Hollander; Philip A Dennis; Kenneth H Kraemer Journal: Proc Natl Acad Sci U S A Date: 2009-03-27 Impact factor: 11.205